Business
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024. Title: 1075-11 - Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 1-Year Follow-Up: Findings From the FOREST-HCM StudyPresenter: Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular CenterSession: 1075 - Bulking Up: Advances in Hypertrophic CardiomyopathyDate: April 7, 2024Presentation Time: 2:00 PM-2:10 PM Eastern Time Location: Moderated Poster Theater 03 Title: 1226-128 - Association Between Beta Blocker Use and Incidence of New Atrial Fibrillation and Flutter Post-Septal Myectomy for Obstructive Hypertrophic CardiomyopathyPresenter: Morris M. Kim, M.D., Cardiovascular Disease Fellow, Oregon Health & Science UniversitySession: 1226 - Heart Failure and Cardiomyopathies: Special Populations 02Date: April 6, 2024Presentation Time: 10:45 AM-11:30 AM Eastern Time Location: Hall B4-5 Title: 1343-122 - Standard of Care Medication Patterns of Use Before and After Septal Myectomy in Patients with Obstructive Hypertrophic CardiomyopathyPresenter: Tristan B. Post, M.D., Clinical Research Coordinator, Oregon Health & Science UniversitySession: 1343 - Heart Failure and Cardiomyopathies: Pharmacology 08Date: April 7, 2024Presentation Time: 9:15 AM-10:00 AM Eastern Time Location: Hall B4-5 Title: 1075-03 - Racial and Ethnic Differences in Cardiovascular Outcomes in Patients Diagnosed with Hypertrophic CardiomyopathyPresenter: Nosheen Reza, M.D., Assistant Professor of Medicine, Perelman School of Medicine at the University of PennsylvaniaSession: 1075 - Bulking Up: Advances in Hypertrophic CardiomyopathyDate: April 7, 2024Presentation Time: 1:00 PM-1:10 PM Eastern Time Location: Moderated Poster Theater 03 About Cytokinetics Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is c...